New York-based longevity science company Elysium Health Inc announced on Wednesday that it has introduced VISION by Elysium Health for eye longevity, performance, and protection.
The product was developed with the guidance of Theodore Leng, MD, a retinal specialist, ophthalmologist, and director of Clinical and Translational Research at the Byers Eye Institute at Stanford University School of Medicine.
According to the company, VISION by Elysium Health is formulated to support visual performance and eye health at every stage of life and is based on the latest research on xanthophyll carotenoids -- plant pigments that accumulate in the eye and provide powerful antioxidant defence and photoprotection -- with Elysium Health's Protective Intervention for Xanthin-based Eye Longevity (PIXEL) Complex.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline